Abstract：
Major depressive disorder (MDD) is characterized by high rates of disability and death and has become a public health problem that threatens human life and health worldwide. HPA axis disorder and neuroinflammation are two common biological abnormalities in MDD patients. Hsp90 is an important molecular chaperone that is widely distributed in the organism. Hsp90 binds to the co-chaperone and goes through a molecular chaperone cycle to complete its regulation of the client protein. Numerous studies have demonstrated that Hsp90 regulates how the HPA axis reacts to stress and how GR, the HPA axis\' responsive substrate, matures. In addition, Hsp90 exhibits pro-inflammatory effects that are closely related to neuroinflammation in MDD. Currently, Hsp90 inhibitors have made some progress in the treatment of a variety of human diseases, but they still need to be improved. Further insight into the role of Hsp90 in MDD provides new ideas for the development of new antidepressant drugs targeting Hsp90.
摘要：
重度抑郁症(MDD)的特点是高致残率和死亡率,已成为全球威胁人类生命和健康的公共卫生问题。HPA轴紊乱和神经炎症是MDD患者常见的两种生物学异常。Hsp90是一种重要的分子伴侣,广泛分布于生物体内。Hsp90与共伴侣结合并经历分子伴侣循环以完成其对客户蛋白的调节。大量研究表明，Hsp90调节HPA轴对压力的反应以及GR的反应。HPA轴响应底物，成熟。此外,Hsp90表现出与MDD中的神经炎症密切相关的促炎作用。目前,Hsp90抑制剂在治疗多种人类疾病方面取得了一定的进展,但是它们仍然需要改进。进一步深入了解Hsp90在MDD中的作用,为开发靶向Hsp90的新型抗抑郁药物提供了新思路。
